SSTR2 and meningioma: Despite the positive results, this study has some limitations to address in the future: (1) The full evaluation of toxicology and the treatment optimization of the SSTR2 ADC have not been performed; (2) The developed anti-SSTR2 mAb can be further engineered (such as by humanization) to meet the clinical requirement in the future; and (3) Alternative animal models such as the patient-derived xenograft (PDX) model or the humanized model should be developed to further evaluate the meningioma treatment efficiency.